Sr. Medical Director, Hematology/Oncology (MD Required)

AbelZeta•Rockville, MD

1h•$303,515 - $413,634

About The Position

AbelZeta is seeking a physician clinical developer to join its Oncology Clinical Development organization. The successful candidate will initially provide study-level clinical leadership and medical monitoring for the C-CAR039 oncology program, an autologous CD20/CD19 CAR-T therapy being developed for relapsed/refractory large B-cell lymphoma (LBCL). The role includes meaningful responsibility for protocol design, study execution, investigator engagement, safety oversight, data interpretation, and regulatory support. The position offers the opportunity to contribute to a rapidly evolving clinical-stage cell-therapy organization as programs move from early clinical evidence toward global and potentially registrational development. The successful candidate can build expertise in oncology cell therapy and progressively expand from hands-on study leadership to broader clinical development ownership.

Requirements

MD, DO, or equivalent medical degree.
Board certification or board eligibility in Hematology, Medical Oncology, Hematology/Oncology, or another specialty with substantial expertise in hematologic malignancies.
Meaningful clinical experience caring for patients with hematologic malignancies, particularly B-cell lymphomas such as relapsed/refractory LBCL.
Demonstrated understanding of clinical-trial methodology, GCP, patient safety, and clinical data interpretation.
Strong written and verbal communication skills and the ability to operate effectively in a highly matrixed, fast-moving environment.

Nice To Haves

Industry clinical-development experience as a study physician or medical monitor, other clinical development experience, or experience as an academic clinical trial investigator.
Hands-on medical monitoring and EDC/data-review experience, including eligibility, AEs/SAEs, concomitant medications, protocol deviations, rescue therapy, and medical queries.
Experience designing or executing Phase 1, Phase 1b/2, Phase 2, pivotal, or registrational clinical trials.
Experience with CAR-T, cell therapy, gene therapy, hematopoietic stem-cell transplantation, immune effector-cell therapy, or other advanced therapeutic modalities.
Experience with biomarkers, translational medicine, precision medicine, pharmacodynamic endpoints, or mechanistically driven patient-selection strategies.
Experience supporting regulatory submissions or direct health-authority interactions.
Ability to engage investigators and KOLs as a clinically credible physician peer while maintaining sponsor accountability.
Collaborative approach and effectiveness across Clinical Operations, Safety, Regulatory, Biometrics, Translational Medicine, CMC, Research, and external partners.
Comfort with ambiguity and urgency, including prioritizing, making decisions with incomplete information, and working effectively in a growing biotechnology company.

Responsibilities

Serve as Study Medical Lead for one or more clinical trials and provide day-to-day clinical oversight from study start-up through database lock and clinical study reporting.
Perform or oversee medical monitoring, including eligibility review, adverse events, serious adverse events, concomitant medications, rescue therapy, protocol deviations, and data queries.
Review subject-level clinical data in EDC and related data-review platforms.
Provide medical guidance to investigators and sites on protocol interpretation, eligibility, lymphoma management, safety events, and study-specific clinical questions.
Partner with Clinical Operations, Data Management, Pharmacovigilance/Safety, Biostatistics, Translational Medicine, Regulatory Affairs, Medical Writing, CMC/Technical Operations, and CRO partners.
Lead or contribute to protocols, amendments, investigator brochures, informed consent forms, medical monitoring plans, clinical sections of statistical analysis plans, clinical study reports, and other core study documents.
Integrate lymphoma biology, clinical phenotype, standard of care, translational findings, PK/PD, biomarker data, and emerging safety and efficacy data into study-level decisions and future development strategy.
Identify study risks, propose mitigation strategies, and help ensure high-quality, timely, inspection-ready trial execution.
Participate in regulatory interactions and, with increasing experience, help lead interactions related to expedited programs, protocol alignment, pivotal development, and registrational strategy.
Build productive relationships with investigators, key opinion leaders, advisory boards, patient advocacy organizations, and external experts.
Develop expertise in clinical and operational considerations unique to autologous CAR-T and other advanced therapies, including leukapheresis, manufacturing and vein-to-vein coordination, lymphodepletion, infusion, acute toxicity management, cytopenias, infection risk, immune reconstitution, and long-term follow-up.
Partner with Safety and clinical experts on assessment and management frameworks for CRS, ICANS/neurotoxicity, infections, cytopenias, and oncology-specific complications.